Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Open access
Waage, Anders, Gimsing, Peter, Fayers, Peter, Abildgaard, Niels, Ahlberg, Lucia, Björkstrand, Bo, Carlson, Kristina, Dahl, Inger Marie, Forsberg, Karin, Gulbrandsen, Nina, Haukås, Einar, Hjertner, Øyvind, Hjorth, Martin, Karlsson, Torbjörn, Knudsen, Lene Meldgaard, Nielsen, Johan Lanng, Linder, Olle, Mellqvist, Ulf-Henrik, Nesthus, Ingerid, Rolke, Jürgen, Strandberg, Maria, Sørbø, Jon Hjalmar, Wisløff, Finn, Juliusson, Gunnar, Turesson, Ingemar, for the Nordic Myeloma Study Group · 2010 · Blood

Abstract

In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The dose of thalidomide/placebo was escalated to 400 mg daily until plateau phase and thereafter reduced to 200 mg daily until progression. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the MPT and MP arms, respectively (P < .001). There was no significant difference in progression-free or overall survival, with median survival being 29 months in the MPT arm and 32 months in the MP arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Constipation, neuropathy, nonneuropathy neurologic toxicity, and skin reactions were significantly more frequent in the MPT arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, MPT had a significant antimyeloma effect, but this did not translate into improved survival. This trial was registered at www.clinicaltrials.gov as #NCT00218855.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-08-237974

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 230

Metadata

Authors
Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I. M., Forsberg, K., Gulbrandsen, N., Haukås, E., Hjertner, Ø., Hjorth, M., Karlsson, T., Knudsen, L. M., Nielsen, J. L., Linder, O., Mellqvist, U.-H., Nesthus, I., Rolke, J., Strandberg, M., Sørbø, J. H., Wisløff, F., Juliusson, G., Turesson, I., & for the Nordic Myeloma Study Group
Venue
Blood
Published
2010-09-02
Volume
116
Issue
9
Pages
1405-1412
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2028399237
Cited by
230
References
4
FWCI
20.29
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2009-08-237974
The paper
Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I. M., Forsberg, K., Gulbrandsen, N., Haukås, E., Hjertner, Ø., Hjorth, M., Karlsson, T., Knudsen, L. M., Nielsen, J. L., Linder, O., Mellqvist, U.-H., Nesthus, I., . . . for the Nordic Myeloma Study Group. (2010). Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. https://doi.org/10.1182/blood-2009-08-237974

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.